Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.65 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.47 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10334603 | 0.95 | PDPK1 (0.60) | SLC6A3SLC6A4PDPK1MEN1KMT2A | |
| SCHEMBL6075209 | 0.83 | SLC6A3 (0.68) | SLC6A3SLC6A4 | |
| SCHEMBL9016828 | 0.82 | SLC6A3 (0.51) | SLC6A3SLC6A4LMNA | |
| SCHEMBL8740849 | 0.82 | SLC6A3 (0.58) | SLC6A3SLC6A4PDPK1 | |
| SCHEMBL2577670 | 0.82 | SLC6A3 (0.65) | SLC6A3SLC6A4PDPK1CYP2C9CYP3A4 | |
| SCHEMBL16011837 | 0.81 | ALDH1A1 (0.51) | SLC6A3SLC6A4MEN1KMT2APOLB | |
| SCHEMBL9016798 | 0.81 | SLC6A3 (0.46) | SLC6A3 | |
| SCHEMBL6074974 | 0.80 | SLC6A3 (0.59) | SLC6A3SLC6A4 | |
| SCHEMBL10489660 | 0.80 | PDPK1 (0.68) | SLC6A3SLC6A4PDPK1MEN1KMT2A | |
| SCHEMBL6074941 | 0.80 | SLC6A3 (0.64) | SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11555013-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | THE USA, AS REPRESENTED BY THE SECRETARY, DHHS (US) | 2023-01-17 | — | — | US | disclosed |
| EP-2964611-B1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | US HEALTH (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20210130288-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-05-06 | — | — | US | disclosed |
| US-10913711-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-09 | — | — | US | disclosed |
| US-10590074-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190185424-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2019-06-20 | — | — | US | disclosed |
| US-20180093947-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | US HEALTH (US) | 2018-04-05 | — | — | US | disclosed |
| US-9862679-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160009644-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | The United States of America, as represented by th Secretary, Department of Health and Human Service (US) | 2016-01-14 | — | — | US | disclosed |
| EP-2964611-A2 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014138518-A2 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-09-12 | — | — | WO | disclosed |
| US-7067538-B2 | MCP-1 receptor antagonists and methods of use thereof | WARNER-LAMBERT COMPANY, LLC (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050171163-A1 | MCP-1 receptor antagonists and methods of use thereof | BRATTON LARRY D (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1539685-A1 | MCP-1 RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | Warner-Lambert Company LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004014847-A1 | MCP-1 RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| US-5571825-A | Method of selectively inhibiting prostaglandin G/H synthase-2 | WARNER-LAMBERT COMPANY (US) | 1996-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185424-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885SLC6A4 2/4885PDPK1 1626/4885 |
| US-20050171163-A1 | MCP-1 receptor antagonists and methods of use thereof | CCR2, CCR1, CCL2 | SLC6A3 1045/4885SLC6A4 1229/4885PDPK1 4322/4885 |
| US-10590074-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885SLC6A4 2/4885PDPK1 1626/4885 |
| US-20210130288-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885SLC6A4 2/4885PDPK1 1626/4885 |
| US-20160009644-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885SLC6A4 2/4885PDPK1 1626/4885 |
| US-11555013-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885SLC6A4 2/4885PDPK1 1626/4885 |
| US-20180093947-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885SLC6A4 2/4885PDPK1 1626/4885 |
| US-10913711-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885SLC6A4 2/4885PDPK1 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.